UCB invests $5 billion to Establish New Biologics Manufacturing Facility in the United States
Introduction:
Global biopharmaceutical company UCB has announced plans to build a new advanced biologics manufacturing facility in the United States. This strategic investment aims to support the company’s expanding presence in one of its fastest-growing markets, while strengthening its supply chain and contributing to local economic development.
Features:
The new facility is part of UCB’s wider ambition to grow its biologics production capabilities and meet rising demand in the U.S.
Approximately 300 permanent, skilled roles in biologics manufacturing will be created, along with more than 500 jobs during the construction phase.
The company is currently assessing potential locations within the U.S., focusing on areas with strong talent pools and innovative life sciences ecosystems.
This development complements UCB’s increasing collaboration with U.S.-based contract manufacturing organisations (CMOs), helping to ensure production support for its current portfolio and
The investment in the new manufacturing facility forms a key part of UCB’s long-term strategy to align its global production with future growth. It also reflects the company’s continued commitment to delivering scientific innovation, strengthening supply resilience, and contributing to sustainable healthcare value.
Specifications:
| Name | UCB |
| Budget | $5 Billion |
| Type | Construction |
